Fluxergy, Mass General Brigham Partner to Evaluate Rapid COVID-19 Molecular Testing System

Jun 30, 2020

|

NEW YORK – Fluxergy said on Monday that it is collaborating with Mass General Brigham (MGB, formerly Partners Healthcare) to evaluate Fluxergy's research-use-only COVID-19 molecular testing platform.

Fluxergy, based in Irvine, California, will specifically work with the MGB Center for COVID Innovation, said Fluxergy Chief Commercialization Officer Ali Tinazli.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

This Time, Novavax

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Shortened Visas for Some Students

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

New York's Own Review

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

Science Papers Examine Y Chromosomes of Archaic Humans, Schistosomiasis Therapeutic Targets

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.

Featured White Papers

Increased DNA Yield and Reduced PCR Duplicates Using the Ionic System

Isotachophoresis Improves Nucleic Acid Extraction and Purification from FFPE Samples

A Real-Time-Assay for the fast and gel-free detection of Rhesus Weak D Type 1/1.1 to Type 3

Fast Real-Time PCR Detection of HLA-B*27 Directly from Blood Using a Specialized Stabilizing Reagent

Sep

30

Featured Webinar

Moving from Non-Invasive Prenatal Screening to Prenatal Diagnostics: An Expert Panel Discussion

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care.

Oct

01

Featured Webinar

Immune Repertoire Sequencing to Uncover SARS-CoV-2-Specific T Cell Responses and Dynamics

T cells are the adaptive immune system’s first responders to any virus, circulating in the blood to detect and quickly multiply to attack the virus, and also support the development of antibodies by B cells.

Oct

08

Featured Webinar

Novel Applications of RNA-based Precision Oncology: From Drug Tolerability to Immunogenomics

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Oct

14

Featured Webinar

Application of ctDNA Analysis to Detect MRD and Predict Recurrence in Colorectal Cancer

Circulating tumor DNA (ctDNA) can allow clinicians and researchers to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy or selected for clinical trials.

Menu

Fluxergy, Mass General Brigham Partner to Evaluate Rapid COVID-19 Molecular Testing System

To read the full story....

Breaking News

M2Gen Expands Partnership With Discovery Life Sciences

Mutations in Type I Interferon Immunity Genes Underlie Severe COVID-19

Palmetto Expands Coverage for Decipher Biosciences Prostate Cancer Test

Cepheid Multiplex SARS-CoV-2, Flu, RSV Test Nabs FDA Emergency Use Authorization

ASU Team Wins $6M in Government Funding to Develop Rapid Saliva Testing System for Coronavirus

In Brief This Week: Fluidigm, Thermo Fisher Scientific, Veracyte, and More

The Scan

This Time, Novavax

Shortened Visas for Some Students

New York's Own Review

Science Papers Examine Y Chromosomes of Archaic Humans, Schistosomiasis Therapeutic Targets

Featured White Papers

Moving from Non-Invasive Prenatal Screening to Prenatal Diagnostics: An Expert Panel Discussion

Immune Repertoire Sequencing to Uncover SARS-CoV-2-Specific T Cell Responses and Dynamics

Novel Applications of RNA-based Precision Oncology: From Drug Tolerability to Immunogenomics

Application of ctDNA Analysis to Detect MRD and Predict Recurrence in Colorectal Cancer

What's Popular?

Cepheid Multiplex SARS-CoV-2, Flu, RSV Test Nabs FDA Emergency Use Authorization

BGI Genomics Gets CE Mark for Multiplexed SARS-CoV-2, Influenza Tests

Abacus Diagnostica Readying Multiplex RT-PCR Test for SARS-CoV-2, Flu, RSV

Genetron, CStone Launch Clinical Trial to Develop CDx for Cancer Drug Avapritinib

NIH Awardee MatMaCorp Developing SARS-CoV-2 Molecular Test for Rural Hospitals

Sponsorships